Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-Low and HER2-Ultralow Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of trastuzumab deruxtecan (T-DXd) for patients with metastatic, HER2-low and HER2-ultralow breast cancer.